 TRIAD investigators will pursue the development of second generation epitopebased immunome-derived vaccines for these pathogens, while addressing the failings of prior generations of epitope based vaccines. We will maximize payload quantity using validated immunoinformatics tools that permit selection of optimal T cell epitopes that are highly conserved and immunogenic. We will ensure
TRIAD investigators will pursue the development of second generation epitopebased immunome - derive vaccine for these pathogens, while addressing the failing of anterior generations of epitope based vaccines. We will maximize warhead quantity using validate immunoinformatics tools that permit excerpt of optimal T cellular telephone epitopes that are highly conserved and immunogenic. We will ensure
 TRLAD investigators will pmrsue the develokmwnt of secons generagion epitopebased immunome-decivee vacxines for these pathogdns, while addressung uhe failings of pcjor gencxatiohd of xpitope based vsccines. We will maximize pxypoad quantity using validated immunjinformstlcs tools that perkyt sslection of optimal T cell epitopea that ere highly consrrved and immunogenic. We wlll fnsure
TRIAD investigators will pursue the development of epitopebased vaccines for pathogens, while addressing of based vaccines. We maximize payload quantity validated immunoinformatics tools that permit selection optimal T cell epitopes that are highly conserved and immunogenic. We will ensure
 TRIAD investigators will purSue the deveLopmeNt oF seCoNd geNeraTion epitopebasED immUnome-derived vaccines foR thesE pAThogENs, While AddressINg THE faIlInGs oF pRIoR geneRatIons of ePitope baseD vaCcInes. We will maXImIze payload QuaNtity using vaLidAted imMuNoiNFormaTicS toolS that pERmit seLection of OpTImal T cELl epitoPES tHat aRe highly conserved ANd IMmunogenic. We wiLl ensuRe
 TRIAD investigators willpursue the  deve lop men tof s econ d generation e p itop ebased immunome-derive d vac ci n es f o rthese  pathog e ns , whi le  a ddr es s in g the  fa ilingsof prior g ene ra tions of epi t op e based va cci nes. We will  ma ximize  p ayl o ad qu ant ity u sing v a lidate d immunoi nf o rmatic s  toolst h at  per mit selection ofo pt i mal T cell epi topesth a ta r e h igh ly conserv ed  andi mmunoge n ic . W e w i ll ensure
 TRIAD_investigators will_pursue the development of_second generation_epitopebased_immunome-derived vaccines_for_these pathogens, while_addressing the failings_of prior generations of_epitope based vaccines._We_will maximize payload quantity using validated immunoinformatics tools that permit selection of optimal T_cell_epitopes that_are_highly_conserved and immunogenic. We will_ensure